Apotex Research Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Apotex Research Private Limited Pharmaceutical Export Portfolio Dataset — 12 Products, $56.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Apotex Research Private Limited — Pharmaceutical Exporter Profile (2026) | 12 Products, $56.3M Trade | TransData Nexus

Apotex Research Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $56.3M Total Trade · DGFT Verified

Apotex Research Private Limited is an Indian pharmaceutical exporter with a total trade value of $56.3M across 12 products in 4 therapeutic categories. Based on 1,280 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Apixaban ($18.1M), Rosuvastatin ($7.8M), Atorvastatin ($6.2M).

Apotex Research Private Limited — Export Portfolio & Destination Treemap

Apotex Research Private Limited pharmaceutical export portfolio — 12 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Apotex Research Private Limited? — Company Overview & Market Position

Apotex Research Private Limited, incorporated on June 16, 2003, is a private unlisted company based in Bangalore, Karnataka, India. The company is registered under the Corporate Identification Number (CIN) U73100KA2003PTC032103. Its authorized capital stands at ₹460 crore, with a paid-up capital of ₹291.86 crore. The registered office is located at Site No.1, Bommasandra Industrial Area, 4th Phase, Jigani Link Road, Jigani Hobli, Karnataka 562158.

Apotex Research Private Limited specializes in the research and development of pharmaceutical formulations, focusing on finished dosage forms such as tablets, capsules, syrups, and injections. The company has a significant presence in the Indian pharmaceutical export market, with a total export value of $56.3 million USD and 1,280 shipments across 12 products in four therapeutic categories. The top five products include Apixaban ($18.1 million, 10.0% market share), Rosuvastatin ($7.8 million, 1.7% market share), Atorvastatin ($6.2 million, 0.6% market share), Amino ($4.1 million, 1.3% market share), and Acetaminophen ($3.7 million, 1.6% market share).

What Does Apotex Research Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Apixaban$18.1M

Product Portfolio — Top 12 by Export Value

Apotex Research Private Limited exports 12 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Apixaban	Cardiovascular	$18.1M	361	10.0%	2
2	Rosuvastatin	Cardiovascular	$7.8M	155	1.7%	13
3	Atorvastatin	Cardiovascular	$6.2M	124	0.6%	14
4	Amino	Nutritional Supplements	$4.1M	86	1.3%	12
5	Acetaminophen	Analgesics & Antipyretics	$3.7M	80	1.6%	7
6	Naproxen	Analgesics & Antipyretics	$3.5M	86	2.6%	11
7	Celecoxib	Analgesics & Antipyretics	$3.2M	77	2.4%	9
8	Citalopram	CNS & Psychiatric	$2.4M	86	0.9%	15
9	Escitalopram	CNS & Psychiatric	$2.4M	86	1.2%	13
10	Ramipril	Cardiovascular	$2.3M	65	2.6%	11
11	Rivaroxaban	Cardiovascular	$2.3M	54	4.3%	6
12	Pravastatin	Cardiovascular	$409.3K	20	1.3%	7

Apotex Research Private Limited exports 12 pharmaceutical products across 4 therapeutic categories with a total export value of $56.3M. The top category is Cardiovascular (65.7% of portfolio), followed by Analgesics & Antipyretics (18.5%), indicating a concentrated portfolio with the top 5 products accounting for 70.7% of total export value.

Apotex Research Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Apotex Research Private Limited operates a manufacturing facility located in Bommasandra Industrial Area, Jigani Hobli, Karnataka. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the facility is equipped to handle large-scale manufacturing to meet both domestic and international demand. The plant adheres to Good Manufacturing Practices (GMP) to ensure the quality and safety of its products.

3Key Leadership

The leadership team at Apotex Research Private Limited comprises experienced professionals:

Goutam Vilas Pujari: Director
Brian McClelland George: Director
Yoganjaneya Reddy Panem: Director
Kajal Palan: Director
Indrajyoti Bose: Director

These individuals bring a wealth of expertise in pharmaceutical research, development, and manufacturing, contributing to the company's strategic direction and operational success.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Apotex Research Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Apotex Research Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for various products, indicating a commitment to meeting stringent regulatory standards. However, in August 2018, the FDA issued a warning letter to Apotex Research Private Limited, citing violations of Current Good Manufacturing Practice (CGMP) regulations. The FDA recommended engaging a qualified consultant to assist in meeting CGMP requirements.

In the European Union, Apotex Research Private Limited has obtained marketing authorizations for several products, facilitating market access across member states. The company has also secured approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom and the Therapeutic Goods Administration (TGA) in Australia, enabling the distribution of its products in these regions. In Japan, Apotex Research Private Limited has engaged in regulatory filings, though specific approval statuses are not publicly disclosed.

2Emerging Markets

Apotex Research Private Limited has expanded its footprint into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company has pursued World Health Organization (WHO) prequalification for certain products, which is a critical step for gaining access to these markets. WHO prequalification ensures that products meet international standards of quality, safety, and efficacy, facilitating procurement by United Nations agencies and other international organizations. This strategic move enhances the company's ability to serve a broader patient population in developing regions.

Apotex Research Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Apotex Research Private Limited has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for various products, indicating a proactive approach to entering the U.S. market. However, in August 2018, the FDA issued a warning letter to Apotex Research Private Limited, citing violations of Current Good Manufacturing Practice (CGMP) regulations. The FDA recommended engaging a qualified consultant to assist in meeting CGMP requirements.

2WHO & EU GMP

Apotex Research Private Limited has obtained Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU). These certifications validate the company's adherence to international standards in pharmaceutical manufacturing, ensuring the quality and safety of its products. The EU GMP certification facilitates market access across European Union member states, while WHO GMP certification is essential for supplying products to international organizations and emerging markets.

3CDSCO & Indian Regulatory

Apotex Research Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Apotex Research Private Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products. The company's top five products—Apixaban, Rosuvastatin, Atorvastatin, Amino, and Acetaminophen—compete with offerings from other generic pharmaceutical manufacturers. Market share data indicates that Apotex Research Private Limited holds a 10.0% share in Apixaban, a 1.7% share in Rosuvastatin, a 0.6% share in Atorvastatin, a 1.3% share in Amino, and a 1.6% share in Acetaminophen. These figures suggest that while the company has a presence in these therapeutic categories, it faces competition from other manufacturers with larger market shares.

2Key Differentiators

Apotex Research Private Limited's key differentiators include its focus on high-quality, affordable pharmaceutical formulations and its commitment to obtaining international regulatory approvals. The company's product portfolio spans multiple therapeutic categories, including cardiovascular, analgesics and antipyretics, and central nervous system (CNS) and psychiatric disorders. This diversification allows the company to address a broad spectrum of patient needs. Additionally, Apotex Research Private Limited's adherence to Good Manufacturing Practices (GMP) and its pursuit of WHO prequalification and EU GMP certifications underscore its dedication to maintaining high manufacturing standards.

Buyer Due Diligence Brief — Evaluating Apotex Research Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Apotex Research Private Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $56.3 million USD and 1,280 shipments across 12 products. The company's adherence to Good Manufacturing Practices (GMP) and pursuit of international certifications, such as WHO prequalification and EU GMP, indicate a commitment to quality

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Apotex Research Private Limited

How many pharmaceutical products does Apotex Research Private Limited export from India?

Apotex Research Private Limited exports 12 pharmaceutical products across 4 therapeutic categories. The top exports are Apixaban ($18.1M), Rosuvastatin ($7.8M), Atorvastatin ($6.2M), Amino ($4.1M), Acetaminophen ($3.7M). Total export value is $56.3M.

What is Apotex Research Private Limited's total pharmaceutical export value?

Apotex Research Private Limited's total pharmaceutical export value is $56.3M, based on 1,280 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Apotex Research Private Limited cover?

Apotex Research Private Limited exports across 4 therapeutic categories. The largest are Cardiovascular (65.7%, 6 products), Analgesics & Antipyretics (18.5%, 3 products), CNS & Psychiatric (8.6%, 2 products).

Get Full Apotex Research Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.